Nathan Rabinovitch, MD, MPH

Special Interests

Research Interests

Dr. Rabinovitch’s current research focuses on the role of environmental triggers and biomarkers of susceptibility in asthma. These spotlight the effects of ambient air pollution, environmental tobacco smoke and bioaerosols on asthma severity and identifies biomarkers which can be used to individualize medical therapy in asthma.

Education

Education

1989

Mcgill University Medical School, MD

Residency

1992

Albert Einstein College of Medicine, Pedatrics

Fellowship

1997

National Jewish Health, Pediatrics, Allergy and Immunology

Awards & Recognition

2014: Best Doctors in America, Best Doctors, Inc.
2007-2008: Best Doctors in America: Allergy/Immunology

Board Certification

American Board of Allergy and Immunology

Professional Memberships

AAAAI

Publications

N. Rabinovitch, M. Strand, K. Stuhlman, E.W. Gelfand. Exposure to Tobacco Smoke Increases LTE4-Related Albuterol Usage and Response to Montelukast. 2008 Journal of Allergy and Clinical Immunology 2008:121: 1365-1371.

N. Rabinovitch. Urinary Leukotriene E4. Immunology and Allergy Clinics of North America 2007; 27(4): 651-664.

N. Rabinovitch, L. Zhang, E.W. Gelfand. Urine LTE4 Levels are Associated with Decreased PFTs in Children with Persistent Airway Obstruction. Journal of Allergy and Clinical Immunology 2006; 118: 635-40.

N. Rabinovitch, M. Strand, E.W. Gelfand. Particulate Levels are Associated with Early Asthma Worsening in Children with Persistent Disease. American Journal of Respiratory and Critical Care Medicine 2006; 173: 1098-1105.

N. Rabinovitch, A.H. Liu, L. Zhang, C.E. Rodes, K. Foard, S.J. Dutton, J.R. Murphy, E.W. Gelfand. Importance of the Personal Endotoxin Cloud in School-Age Children with Asthma. Journal of Allergy and Clinical Immunology 2005; 116: 1053-1057.

Hospital Affiliations

• Rocky Mountain Hospital for Children

Academic Affiliations

Professor of Pediatrics at the University of Colorado Denver

Conflicts of Interest

National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.